SCHEMBL2353482

SCHEMBL2353482

CCCCCC(CCCC)(CCCCC)CC(N)CO

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 5/20 0.37
CYP2D6 P10635 4/20 0.37
MAPT P10636 4/20 0.37
LMNA P02545 4/20 0.37
GMNN O75496 3/20 0.37
POLB P06746 3/20 0.37
BLM P54132 3/20 0.37
CETP P11597 3/20 0.37
UBE2N P61088 3/20 0.37
THPO P40225 2/20 0.37
TP53 P04637 2/20 0.37
CYP1A2 P05177 2/20 0.37
MTOR P42345 1/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP3A4 P08684 1/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GLA P06280 2/20 0.36
THRB P10828 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096924 0.73 LMNA (0.38) SPHK1CYP2D6MAPTLMNAGMNN
SCHEMBL23627333 0.72 LMNA (0.41) SPHK1CYP2D6MAPTLMNAGMNN
SCHEMBL2349627 0.72 LMNA (0.48) LMNAMEN1KMT2AALDH1A1FDPS
SCHEMBL23627552 0.72 LMNA (0.41) SPHK1CYP2D6MAPTLMNAGMNN
SCHEMBL2343802 0.71 ALDH1A1 (0.52) LMNACYP3A4ALDH1A1
SCHEMBL11292977 0.71 SMN1; SMN2 (0.43) LMNAMEN1KMT2ATHRBALDH1A1
SCHEMBL11445128 0.71 SMN1; SMN2 (0.43) LMNAMEN1KMT2ATHRBALDH1A1
SCHEMBL9633323 0.69 TSHR (0.47) LMNATHRBFDPSSMPD1GGPS1
SCHEMBL23436516 0.69 LMNA (0.42) SPHK1CYP2D6MAPTLMNAGMNN
SCHEMBL693176 0.69 LMNA (0.46) LMNAMEN1KMT2ATHRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989480-B2 Aryl amino acid derivatives as inhibitors for treating inflammation DECODE GENETICS EHF (IS) 2011-08-02 US disclosed
US-7989480-B2 Aryl amino acid derivatives as inhibitors for treating inflammation DECODE GENETICS EHF (IS) 2011-08-02 US disclosed
EP-2066800-A2 ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION Decode Genetics EHF (IS) 2009-06-10 EP disclosed
EP-2066800-A2 ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION Decode Genetics EHF (IS) 2009-06-10 EP disclosed
WO-2008019306-A3 ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION DECODE GENETICS EHF (IS) 2008-04-17 WO disclosed
WO-2008019306-A2 ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION DECODE GENETICS EHF (IS) 2008-02-14 WO disclosed
WO-2008019306-A2 ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION DECODE GENETICS EHF (IS) 2008-02-14 WO disclosed
US-20080033024-A1 ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION DECODE GENETICS EHF. (IS) 2008-02-07 US disclosed
US-20080033024-A1 ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION DECODE GENETICS EHF. (IS) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033024-A1 ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION LTA4H, LTB4R2, LTB4R SPHK1 2199/4885CYP2D6 522/4885MAPT 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.